Clinical Trials Logo

Clinical Trial Summary

Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System


Clinical Trial Description

The hypothesis behind the proposed trial of surfactant therapy for COVID-19 infected patients requiring ventilator support is that endogenous surfactant is dysfunctional. This could be due to decreased concentration of surfactant phospholipid and protein, altered surfactant phospholipid composition, surfactant protein proteolysis and/or oedema protein inhibition of surfactant surface tension function and/or oxidative inactivation of surfactant proteins. Variations of these dysfunctional mechanisms have been reported in a range of lung diseases, including cystic fibrosis and severe asthma, and in child and adult patients with ARDS. Our studies of surfactant metabolism in adult ARDS patients showed altered percentage composition of surfactant PC, with decreased DPPC and increased surface tension-inactive unsaturated species, and decreased concentrations of both total PC and phosphatidylglycerol (PG) The SARS-CoV-2 virus binds to the angiotensin converting enzyme-2 (ACE2) receptor, which is preferentially expressed in the peripheral lung ATII cells. Consequent viral infection of ATII cells could reduce cell number and impair the capacity of the lungs to synthesise and secrete surfactant. This, however, has not yet been demonstrated empirically in COVID-19 patients. If this is the case, then exogenous surfactant administration to the lungs is potential one treatment option to mitigate disease severity in these patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04362059
Study type Interventional
Source University Hospital Southampton NHS Foundation Trust
Contact
Status Completed
Phase N/A
Start date June 18, 2020
Completion date January 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT00369759 - An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants N/A
Completed NCT01907659 - Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections N/A
Completed NCT00388921 - High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM N/A
Completed NCT02211729 - A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children Phase 3
Recruiting NCT03093220 - Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis N/A
Recruiting NCT01167686 - Effects of Gardemont S.A Food Supplement on Upper Respiratory Illness Phase 2
Completed NCT00514670 - A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program N/A
Completed NCT02927743 - Effect of Evidence-based Reminders on Use of Antibiotics N/A
Completed NCT02438293 - 'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
Completed NCT00533182 - Influenza in People With Normal and Weakened Immune Systems
Completed NCT01909128 - Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms Phase 3
Completed NCT00144040 - Improving Antibiotic Use in Acute Care Treatment N/A
Recruiting NCT05474430 - Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
Completed NCT01443728 - Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT02491164 - Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe Early Phase 1
Completed NCT01390753 - Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants N/A